超滤腹水回输对肝硬化腹水肾血管调节因子及RAAS系统的影响

王鑫，黄小平，车娅，王亚红，曹晓丽

（陕西省西安市第九医院，陕西 西安，710054）

浏览次数：69次 下载次数：340次

摘要：

目的 研究超滤腹水回输对肝硬化腹水患者肾血管调节因子及RAAS系统的影响。方法 随机选择我院2010年1月至 2012年6月肝硬化顽固性腹水住院患者50例，并给予超滤腹水回输治疗，比较治疗前、后内毒素、血栓素、白三烯、肾素及醛固酮水平。结果 治疗后，患者内毒素、血栓素及白三烯水平均下降，差异有统计学意义（P<0.05）；患者肾素及醛固酮水平均下降，差异有统计学意义（P<0.05）。结论 超滤腹水回输可减低肾血管调节因子活性，并抑制RAAS系统，提示该方法可能通过抑制肾脏血管活性因子活性，改善肾血流作用，进而抑制RAAS 系统激活，为超滤腹水回输提供理论依据。

关键词：肝硬化；腹水；超滤回输；肾血管调节因子

中图分类号：R575.2文献标志码：A文章编号：2096-1413(2017)19-0037-02

Effect of ascites ultrafiltration back-transfusion on renal vascular regulation factor and RAAS system in cirrhotic ascites
WANG Xin, HUANG Xiao-ping, CHE Ya, WANG Ya-hong, CAO Xiao-li


(Ninth Hosptial of Xi``an, Xi``an 710054, China)

ABSTRACT: Objective To observe the impact of ascites ultrafiltration back-transfusion on renal vascular regulation factor and RAAS system in cirrhotic ascites. Methods Fifty cases of hospitalized patients with intractable ascites of cirrhosis from January 2010 to June 2012 were randomly selected and given ascites ultrafiltration back-transfusion therapy. The levels of endotoxin, thromboxane, leukotriene, renin and aldosterone were compared before and after treatment. Results After treatment, the levels of endotoxin, thromboxane and leukotriene of patients decreased (P<0.05). The levels of renin and aldosterone of patients decreased (P<0.05). Conclusion Ascites ultrafiltration back-transfusion can reduce the activity of renal vascular regulation factor and inhibit RAAS system. It shows that this therapy may inhibit the activity of renal vascular regulation factor, improve the renal blood flow, then inhibit the activity of RAAS system, which provides the theoretical basis for the ascites ultrafiltration back-transfusion.
KEYWORDS: liver cirrhosis; ascites; ultrafiltration back-transfusion; renal vascular regulation factor

参考文献：
[1] 崔琰,贾继东.2004 年全国肝病学会关于肝硬化腹水治疗的推荐意义[J].中华肝脏病杂志,2004,12(9):572-573.
[2] KUIPER JJ,BOOMSMA F,VAN BUREN H,et al.Components of the renin-angiotensin-aldosterone system in plasma and ascites in hepatic cirrhosis[J].Eur J Clin Invest,2008,38(12):939-944.
[3] 田军.肝硬化合并难治性腹水的临床诊治[J].临床与实践,2014,12(7):26-27.
[4] 郭连恰,刘沛.肝肾综合征血管收缩机制的研究进展[J].世界华人消化杂志,2008,16(9):982-986.
[5] 白艳丽,杨玉珍.肾素、血管紧张素II 及抗利尿激素与肝硬化腹水形成的关系[J].胃肠病学和肝病学杂志,2007,16(1):76-77.
[6] 李贵星,贺勇,罗通行,等.一氧化氮水平、低钠血症和心功能对肝肾综合征发病的影响[J].中华医学杂志,2011,91(36):2534-2537.
[7] HAN DW.Intestinal endotoxemia as a pathogenetic mechanism in liver failure[J].World J Gastroenteral,2002,8(6):961-965.
[8] 高宝秀,聂鑫.I 型肝肾综合征患者前列腺素I2 和血栓素A2 水平分析[J].临床肝胆杂志,2012,11(7):860-862.
[9] KLAHR S.Role of arachidonic acid metabolites in acute renal failure and sepsis[J].Nephrol Dial Transplant,1994,9(S4):52.
[10] NAKATANI Y,FUKUI H,KITANO H,et al.Endotoxin clearance and its relation to hepatic and renal disturbances in rats with liver cirrhosis [J].Liver,2001,21(1):64-70.
[11] 张金龙,黄志刚,莫国生,等.腹水浓缩超滤回输治疗肝硬化顽固性腹水42例[J].中华传染病杂志,2003,21(4):294-295.
[12] WANG H,PARK O,GAO B.NKT cells in liver fibrosis:controversites or complexities[J].J Hepatol,2011,55(5):1166-1167.